GDF-11 (Growth Differentiation Factor 11) vs SNAP-8 (Acetyl Octapeptide-3)
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GDF-11 (Growth Differentiation Factor 11)
TGF-β superfamily member proposed as a 'young blood factor' — circulating GDF-11 declines with age, and young plasma transfusion in parabiosis experiments reversed aging phenotypes in mice. A high-profile but contested research area: some studies show rejuvenating effects in heart, muscle, and brain; others using purified recombinant GDF-11 show cardiac hypertrophy and muscle wasting at pharmacologic doses.
Full profileSNAP-8 (Acetyl Octapeptide-3)
8-amino acid cosmetic peptide active (Acetyl Octapeptide-3) that competes with SNARE complex proteins to reduce neuromuscular signal transmission in facial expression muscles. An extended, more potent version of Argireline (Acetyl Hexapeptide-3). Clinical studies show 26–63% reduction in expression wrinkle depth with twice-daily application, positioning it as a topical botulinum toxin alternative.
Full profile| GDF-11 (Growth Differentiation Factor 11) | SNAP-8 (Acetyl Octapeptide-3) | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | GDF11, Bone Morphogenetic Protein 11, BMP-11, young blood factor | Leuphasyl, Acetyl Octapeptide-3, SNAP-8 peptide, Argireline extension, Acetyl Glutamyl Heptapeptide-3 |
| Evidence | Research-stage | Research-stage |
| Dosing range | 0.1mg/kg–1mg/kg mg/kg, every 3–7 days (SC); research protocols vary widely | 1%–10% %, twice daily topical application |
| Administration | Subcutaneous injection, Intravenous (research) | Topical (serum/cream) |
| Key side effects | Cardiac hypertrophy (at pharmacologic doses — the key safety concern), Muscle wasting and weight loss, Reproductive effects (GDF-11 inhibits spermatogenesis and folliculogenesis), Cachexia-like syndrome at high doses | Very well-tolerated, Rare mild skin irritation or redness, No systemic absorption at cosmetic concentrations, No paralysis risk (partial SNARE competition only) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: GDF-11 (Growth Differentiation Factor 11) — Subcutaneous injection, Intravenous (research); SNAP-8 (Acetyl Octapeptide-3) — Topical (serum/cream).
- Dosing units differ: GDF-11 (Growth Differentiation Factor 11) is dosed in mg/kg, SNAP-8 (Acetyl Octapeptide-3) in % — they operate at different scales.
- Frequency: GDF-11 (Growth Differentiation Factor 11) is typically every 3–7 days (SC); research protocols vary widely; SNAP-8 (Acetyl Octapeptide-3) is twice daily topical application.
How each works
GDF-11 (Growth Differentiation Factor 11)
The 2013–2014 parabiosis studies from Amy Wagers' lab at Harvard proposed GDF-11 as the primary rejuvenating factor in young blood. However, subsequent work by Lee and others showed that purified recombinant GDF-11 at pharmacologic doses caused cardiac hypertrophy, muscle atrophy, and weight loss — opposite of the proposed rejuvenating effects. The field now views GDF-11 as highly dose-sensitive with a narrow therapeutic window, if one exists at all.
SNAP-8 (Acetyl Octapeptide-3)
SNAP-8 mimics the N-terminal domain of SNAP-25, competing for SNARE complex assembly required for acetylcholine vesicle fusion at the neuromuscular junction. This partial inhibition reduces muscle contraction intensity without complete paralysis. Clinical studies demonstrate statistically significant reductions in crow's feet and forehead line depth after 28 days of use at 5–10% concentration.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.